why choose us

Clinical Trials Search

Showing 7,560 of 132,085 result(s)
Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2

Status: COMPLETED

Condition: Atrial Fibrillation

Interventions: Patient with atrial fibrillation ablated per catheter using radiofrequency energy

Date: 2023-09-28

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

Status: COMPLETED

Condition: Bloodstream Infection

Interventions: Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be

Date: 2023-09-28

A Study of DCR-STAT3 in Adults With Solid Tumors

Status: COMPLETED

Condition: Solid Tumor, Adult

Interventions: DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusi

Date: 2023-09-28

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: COMPLETED

Condition: Parkinson's Disease Psychosis

Interventions: pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks

Date: 2023-09-28

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ?65 Years of Age

Status: COMPLETED

Condition: Influenza, Human

Interventions: BIOLOGICAL: aQIV or aTIV - Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg o

Date: 2023-09-28

Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1

Status: Completed

Condition: Post-Traumatic Headache

Interventions: subcutaneous injection around bilateral greater occipital nerves

Date: 2023-09-28

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Status: ACTIVE_NOT_RECRUITING

Condition: Healthy Volunteers

Interventions: Injection; subcutaneous (SC)

Date: 2023-09-28

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Status: Completed

Condition: Medium-chain Acyl-CoA Dehydrogenase Deficiency

Interventions: Open-label design with doses of sodium phenylbutyrate up to 4.0 g;m2;day

Date: 2023-09-28

Impact of an Enhanced Patient Reported Outcome Measurement (PROM) Strategy on PROM Completion Rates

Status: Completed

Condition: PROM

Interventions: Patients randomized to intervention receive both usual PROMs and new PROMs strategy

Date: 2023-09-28